OMER Form 4: Thomas Bumol receives annual 15k stock option award

Rhea-AI Filing Summary

On June 27, 2025, Omeros Corporation (ticker: OMER) granted non-employee director Thomas F. Bumol a stock option for 15,000 common shares at an exercise price of $3.20 per share, as disclosed in this Form 4 filed on July 1, 2025. The award is part of the company’s recurring director compensation program, automatically issued at each annual shareholder meeting to directors who have served at least six months and will continue to serve. The option vests in full on the day prior to the 2026 annual meeting, contingent upon Bumol’s continued board service. Following the grant, Bumol beneficially owns 15,000 derivative securities (options) with direct ownership. No shares of common stock were bought or sold, and no cash consideration changed hands.

The filing is a standard, non-cash compensation event and does not involve open-market transactions, changes in beneficial ownership of outstanding common shares, or the adoption of a Rule 10b5-1 trading plan. As such, it is considered routine in nature and is unlikely to have a material impact on Omeros’s valuation or trading dynamics.

Insights

Financial Analyst

TL;DR Routine director option grant; no immediate valuation impact.

The 15,000-share option award to Director Bumol mirrors Omeros’s established non-employee director compensation policy and represents less than 0.03% of the company’s ~53 million outstanding shares. Because it is a non-cash, at-the-money grant with a one-year vesting cliff, the economic cost is limited to modest dilution if exercised. There is no indication of insider buying or selling of common shares, nor any signaling regarding future operational performance. Consequently, the disclosure is neutral for investors and does not alter the investment thesis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bumol Thomas F.

(Last) (First) (Middle)

201 ELLIOTT AVENUE WEST

(Street)

SEATTLE WA 98119

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OMEROS CORP [ OMER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$3.2	06/27/2025		A		15,000		(2)	06/27/2035	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025.

2. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

	/s/ Peter B. Cancelmo, Attorney-in-Fact	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Omeros (OMER) report on July 1, 2025?

The company reported a grant of 15,000 stock options to Director Thomas F. Bumol, exercisable at $3.20 per share.

When do the granted OMER options vest and expire?

They vest in full the day before the 2026 annual shareholder meeting and expire on June 27, 2035.

Did the Form 4 disclose any purchase or sale of OMER common stock?

No. The filing shows only an option grant; no common shares were bought or sold.

How many OMER derivative securities does Director Bumol own after the grant?

He beneficially owns 15,000 stock options following the reported transaction.

Is the option grant part of a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the transaction was made under a Rule 10b5-1(c) plan.